Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases

Completed · Phase 1/Phase 2

Conditions studied: Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer, Pain

In brief

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone. It is not yet known whether monoclonal antibody is more effective than zoledronate in treating women who have breast cancer and bone metastases. PURPOSE: Randomized phase I/II trial to compare the effectiveness of monoclonal antibody with that of zoledronate in treating women who have breast cancer and bone metastases.

Key facts

Study ID

NCT00060138

Run by

Chugai Pharmaceutical

Starts

2002-11-01

Last updated by the study team

2013-05-15

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Ireland Cancer Center — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.